



February 28, 2001

Dear Pharmacy Provider:

In consideration of requests to reevaluate the recently announced reimbursement strategy for Warfarin products, I can advise that I have directed my staff to withdraw the cap on the prices for these products as outlined in Bulletin 29 Manitoba Drug Benefits and Interchangeability Formulary Amendments. As delineated in the amendment, Taro-Warfarin will be considered eligible as a Part I benefit effective March 1, 2001.

Further, I have directed an additional policy review of our reimbursement strategy for Warfarin products in order to address a number of stakeholder concerns. I expect the review and recommendations to the Minister of Health to be completed as soon as practicable.

On behalf of Manitoba Health I would like to extend my appreciation for your understanding and patience as we successfully address this issue.

Sincerely,

A handwritten signature in black ink, appearing to read "Rick Dedi". The signature is fluid and cursive.

Rick Dedi